|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0035525,
umls-concept:C0035668,
umls-concept:C0087111,
umls-concept:C0205250,
umls-concept:C0205466,
umls-concept:C0220847,
umls-concept:C0332324,
umls-concept:C0391001,
umls-concept:C0439831,
umls-concept:C0871261,
umls-concept:C1510438,
umls-concept:C1704632,
umls-concept:C1704788,
umls-concept:C1706817,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-5-24
|
|
pubmed:abstractText |
Assessing hepatitis C virus (HCV)-RNA levels is integral to response-guided therapy. Rules for early discontinuation and determination of treatment duration were mainly established with HCV-RNA assays with a detection limit of 50IU/ml (COBAS Amplicor HCV [CA]). The currently used real-time PCR-based COBAS Ampliprep/COBAS-TaqMan HCV (CAP-CTM) test has a detection limit of approximately 10IU/ml. It is unknown whether shortening of treatment duration to 16/24 weeks in patients with rapid virological response at week 4 (RVR) and viral loads between 10 and 50IU/ml is possible.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0168-8278
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
52
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
832-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20385421-Antiviral Agents,
pubmed-meshheading:20385421-Drug Monitoring,
pubmed-meshheading:20385421-Drug Resistance, Viral,
pubmed-meshheading:20385421-Drug Therapy, Combination,
pubmed-meshheading:20385421-Genotype,
pubmed-meshheading:20385421-Hepacivirus,
pubmed-meshheading:20385421-Hepatitis C, Chronic,
pubmed-meshheading:20385421-Humans,
pubmed-meshheading:20385421-Interferon-alpha,
pubmed-meshheading:20385421-Polyethylene Glycols,
pubmed-meshheading:20385421-Predictive Value of Tests,
pubmed-meshheading:20385421-RNA, Viral,
pubmed-meshheading:20385421-Randomized Controlled Trials as Topic,
pubmed-meshheading:20385421-Recombinant Proteins,
pubmed-meshheading:20385421-Recurrence,
pubmed-meshheading:20385421-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:20385421-Ribavirin,
pubmed-meshheading:20385421-Viral Load,
pubmed-meshheading:20385421-Viremia
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
|
|
pubmed:affiliation |
Department of Internal Medicine, J.W. Goethe-University Hospital, Frankfurt, Germany. sarrazin@em.uni-frankfurt.de
|
|
pubmed:publicationType |
Journal Article
|
